Exicure (NASDAQ:XCUR – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.
Profitability
This table compares Exicure and Viridian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exicure | N/A | -237.91% | -61.98% |
| Viridian Therapeutics | -1,620.79% | -79.67% | -44.72% |
Insider & Institutional Ownership
42.8% of Exicure shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Exicure and Viridian Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exicure | $500,000.00 | 14.15 | -$4.95 million | ($1.32) | -0.82 |
| Viridian Therapeutics | $70.85 million | 48.18 | -$342.60 million | ($3.84) | -7.83 |
Exicure has higher earnings, but lower revenue than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Exicure has a beta of 3.83, meaning that its share price is 283% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations for Exicure and Viridian Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exicure | 1 | 0 | 0 | 0 | 1.00 |
| Viridian Therapeutics | 1 | 0 | 11 | 0 | 2.83 |
Viridian Therapeutics has a consensus target price of $41.00, suggesting a potential upside of 36.39%. Given Viridian Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than Exicure.
Summary
Viridian Therapeutics beats Exicure on 7 of the 13 factors compared between the two stocks.
About Exicure
Exicure, Inc. is a biotechnology company historically focused on developing nucleic acid-based therapeutics. Its research has centered on spherical nucleic acid (SNA) technology, a platform designed to deliver genetic material into cells and influence disease-related gene activity. The company has pursued potential treatments for conditions including rare genetic disorders and cancer. Its work has included research into therapies intended to address diseases with limited treatment options. Exicure was based in Chicago, Illinois.
About Viridian Therapeutics
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
